Interleukin-1 beta and thiobarbituric acid reactive substance (TBARS) levels after phase I periodontal therapy in patients with chronic periodontitis

Tuter G., Kurtis B., SERDAR M. A.

JOURNAL OF PERIODONTOLOGY, vol.72, no.7, pp.883-888, 2001 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 72 Issue: 7
  • Publication Date: 2001
  • Doi Number: 10.1902/jop.2001.72.7.883
  • Journal Indexes: Science Citation Index Expanded
  • Page Numbers: pp.883-888
  • Keywords: interleukin-1/adverse effects, thiobarbituric acid reactive substances, periodontitis/pathogenesis, free radicals, reactive oxygen species, clinical parameters, GINGIVAL CREVICULAR FLUID, ADULT PERIODONTITIS, LIPID-PEROXIDATION, CYTOKINES, DISEASE, ANTIOXIDANTS


Background: Interleukin-1 beta (IL-1 beta), a potent stimulator of bone resorption, has been implicated in the pathogenesis of periodontal tissue destruction. There is also a clearly defined and substantial role for free radicals or reactive oxygen species in periodontal destruction. The thiobarbituric acid reactive substances (TBARS) is a commonly applied test to measure free radical activity. The aims of this study were to investigate the amount of crevicular IL-1 beta, tissue TBARS levels, and the clinical status of patients with advanced chronic periodontitis and the effect of phase I periodontal therapy on these clinical parameters and measurements.